I am an optimist. It does not seem too much use being anything else.


Winston Churchill


Monday, October 11, 2010

Thomas Jefferson U. gets NIH Grant to study cancer gene activation

Thomas Jefferson University, was awarded a four year $2.5 million grant from the National Institutes of Health Monday for a study of cancer gene activation in lung cancer. Researchers led by Dr. Eric Wickstrom, a professor of biochemistry and molecular biology at Jefferson Medical College of TJU, will use the grant funds to explore imaging techniques to highlight a gene — known as KRAS2 — involved in solid tumors in order to help direct cancer therapy to the gene. TJU is working with Molecular Targeting Technologies Inc. of West Chester, Pa., on the project.

The grant was awarded to TJU by the National Cancer Institute of NIH as part of its academic-industrial program for speeding discoveries to the bedside.

This is great news for the fight against cancer and TJU where Dennis Wright and Dr. Sato continue to perform laboratory testing, cell viability testing, and dosage response work on Wright's new invention.  Perhaps a similar grant will be received soon to assist with this important research and to jump start the toxicology studies.

Wednesday, September 22, 2010

Update from Dennis Wright, Biotech, Biochemical Expert

Scientific research is my life’s work.  Although I've many successes and achieved about 25 issued biotech patents, this project is the highlight of my professional career.  Each of my patents is like a child to me but this one appears more important than all:
 This new compound, or new chemical entity (NCE) has more potential applications, (antineoplastic, antiviral, antibiotic) and worldwide life-saving implications  than all of my previous inventions.
This week’s  lab work emphasized microtitre plate cell viability assay optimization with dose response curves.  All of the lab work at TJU has continued to yield outstanding results.
Back to the lab tomorrow.  We are  continuing pre-clinical testing  and endeavor to enter toxicology testing in anticipation of FDA Investigational New Drug (IND) filing.

Regards,
Dennis

Cancer Scientist Dennis Wright, (Applied Molecular Biologist, Biochemist, Chemical Engineer) & Oncologist Dr. Takami Sato

Over the past 5 weeks I've had to repeatedly pinch myself to make sure I was hearing the words spoken by my cousin, Dennis Wright correctly.  Dennis is a pure scientist who has worked at the lab bench experimenting and creating for over 30 years.  He has always been an apparent genius when it comes to science and music.  He holds multiple advanced degrees in science and has virtual instant recall for music he has played on the piano or accordion.

Yet when he told me that he believed he had invented a completely new chemical entity (NCE), in his words "hitherto unknown to science or man" I was surprised.  I was further shocked when he told me that his experiments showed that the new compound may in fact be the long sought after and much desired "magic bullet" in cancer treatment.  When he mentioned that this new NCE had a success rate of over 90% when tested on established cell lines of brain, liver and skin cancer, I looked him straight in the eye to make sure he appeared to be still in touch with reality.

Most if not all of us have had at least one member of our immediate or extended family struck down by the insidious disease known as cancer.  We have been accustomed to organizations raising funds to promote cancer research but we have been similarly accustomed to never hearing that a cure has been discovered.  Cancer treatments to date all seem to follow one of three traditional courses; surgery to cut the tumor out, radiation to attempt to burn it into submission, or chemotherapy to poison the offending cells.  Recently, there has been some scientific/medical discussion about more targeted therapies and about drugs that may hold off the rapidly regeneration of cancer cells to extend one's life expectancy.

Never, prior to speaking to Dennis Wright and Dr. Takami Sato (a world renowned oncologist researcher at Thomas Jefferson University Hospital in Philadelphia, PA) had I ever heard of a drug, compound or therapy completely eradicating human cancer cells.  The claim made by my cousin seemed too good to be true and frankly I was not convinced until I met and talked with Dr. Sato myself.

Mr. Wright has been intellectualizing his thoughts and concepts for a new cancer cure for over 5 years.  He took those thoughts into his lab over 3 years ago and invented a completely new class of alpha amino acids.  The resulting compound was successfully tested in Wright's lab against brain cancer cell lines, causing an apoptotic cascade (essentially causing the cancer cells to commit suicide).  Thereafter he did dosing experiments on mice and found that doses thousands of times higher than those used to stop the cancer cells, were still not toxic to mice.

Further lab testing both at Wright's lab and at Jefferson University Hospital have verified the initial lab tests and determined that the NCE is also > 90% effective against liver and skin cancer cell lines.  The magnitude of these findings is earth shattering and I await further news on the laboratory test results.

I hope to have Mr. Wright and/or Dr. Sato provide updates to their ongoing potentially life changing research on this blog.

Stay tuned and keep the faith.  It seems that the long sought after effective assistance for some cancer patients may be just around the corner.